PMC:7283670 / 99250-101614 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":2057,"end":2060},"obj":"Body_part"},{"id":"T2","span":{"begin":2139,"end":2142},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma24890"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma24890"}],"text":"Various combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19\nOseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19\nExperimental: lopinavir and ritonavir plus favipiravir\nLopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19\nExperimental: lopinavir and ritonavir plus oseltamivir in mild COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19\nExperimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19\nExperimental: favipiravir lopinavir/ritonavir for mod. To severe\nfavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19\nExperimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe\nCombination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19\nExperimental: darunavir/ritonavir favipiravir chloroquine mod‐severe\nFavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19\nNo intervention: conventional qurantine\nPatient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):\nSARS‐CoV‐2 eradication time\nSecondary (up to 24 weeks):\nNumber of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment\nOther (up to 24 weeks):\nNumber of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020"}

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T197","span":{"begin":2057,"end":2060},"obj":"Body_part"},{"id":"T198","span":{"begin":2139,"end":2142},"obj":"Body_part"}],"attributes":[{"id":"A197","pred":"uberon_id","subj":"T197","obj":"http://purl.obolibrary.org/obo/UBERON_0001460"},{"id":"A198","pred":"uberon_id","subj":"T198","obj":"http://purl.obolibrary.org/obo/UBERON_0001460"}],"text":"Various combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19\nOseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19\nExperimental: lopinavir and ritonavir plus favipiravir\nLopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19\nExperimental: lopinavir and ritonavir plus oseltamivir in mild COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19\nExperimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19\nExperimental: favipiravir lopinavir/ritonavir for mod. To severe\nfavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19\nExperimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe\nCombination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19\nExperimental: darunavir/ritonavir favipiravir chloroquine mod‐severe\nFavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19\nNo intervention: conventional qurantine\nPatient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):\nSARS‐CoV‐2 eradication time\nSecondary (up to 24 weeks):\nNumber of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment\nOther (up to 24 weeks):\nNumber of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020"}

LitCovid-PD-MONDO

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":1068,"end":1069},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T2","span":{"begin":1105,"end":1106},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T3","span":{"begin":1577,"end":1578},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T4","span":{"begin":1614,"end":1615},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T5","span":{"begin":2057,"end":2060},"obj":"http://www.ebi.ac.uk/efo/EFO_0001410"},{"id":"T6","span":{"begin":2139,"end":2142},"obj":"http://www.ebi.ac.uk/efo/EFO_0001410"},{"id":"T798","span":{"begin":111,"end":112},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T799","span":{"begin":528,"end":529},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T800","span":{"begin":565,"end":566},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Various combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19\nOseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19\nExperimental: lopinavir and ritonavir plus favipiravir\nLopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19\nExperimental: lopinavir and ritonavir plus oseltamivir in mild COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19\nExperimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19\nExperimental: favipiravir lopinavir/ritonavir for mod. To severe\nfavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19\nExperimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe\nCombination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19\nExperimental: darunavir/ritonavir favipiravir chloroquine mod‐severe\nFavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19\nNo intervention: conventional qurantine\nPatient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):\nSARS‐CoV‐2 eradication time\nSecondary (up to 24 weeks):\nNumber of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment\nOther (up to 24 weeks):\nNumber of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020"}

LitCovid-PD-CHEBI

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T858","span":{"begin":0,"end":278},"obj":"Sentence"},{"id":"T859","span":{"begin":279,"end":354},"obj":"Sentence"},{"id":"T860","span":{"begin":355,"end":409},"obj":"Sentence"},{"id":"T861","span":{"begin":410,"end":586},"obj":"Sentence"},{"id":"T862","span":{"begin":587,"end":657},"obj":"Sentence"},{"id":"T863","span":{"begin":658,"end":745},"obj":"Sentence"},{"id":"T864","span":{"begin":746,"end":822},"obj":"Sentence"},{"id":"T865","span":{"begin":823,"end":932},"obj":"Sentence"},{"id":"T866","span":{"begin":933,"end":987},"obj":"Sentence"},{"id":"T867","span":{"begin":988,"end":997},"obj":"Sentence"},{"id":"T868","span":{"begin":998,"end":1198},"obj":"Sentence"},{"id":"T869","span":{"begin":1199,"end":1267},"obj":"Sentence"},{"id":"T870","span":{"begin":1268,"end":1437},"obj":"Sentence"},{"id":"T871","span":{"begin":1438,"end":1506},"obj":"Sentence"},{"id":"T872","span":{"begin":1507,"end":1752},"obj":"Sentence"},{"id":"T873","span":{"begin":1753,"end":1792},"obj":"Sentence"},{"id":"T874","span":{"begin":1793,"end":1901},"obj":"Sentence"},{"id":"T875","span":{"begin":1902,"end":1929},"obj":"Sentence"},{"id":"T876","span":{"begin":1930,"end":1957},"obj":"Sentence"},{"id":"T877","span":{"begin":1958,"end":2222},"obj":"Sentence"},{"id":"T878","span":{"begin":2223,"end":2246},"obj":"Sentence"},{"id":"T879","span":{"begin":2247,"end":2364},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Various combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19\nOseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19\nExperimental: lopinavir and ritonavir plus favipiravir\nLopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19\nExperimental: lopinavir and ritonavir plus oseltamivir in mild COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19\nExperimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19\nExperimental: favipiravir lopinavir/ritonavir for mod. To severe\nfavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19\nExperimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe\nCombination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19\nExperimental: darunavir/ritonavir favipiravir chloroquine mod‐severe\nFavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19\nNo intervention: conventional qurantine\nPatient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):\nSARS‐CoV‐2 eradication time\nSecondary (up to 24 weeks):\nNumber of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment\nOther (up to 24 weeks):\nNumber of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020"}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T281","span":{"begin":2177,"end":2197},"obj":"Phenotype"},{"id":"T282","span":{"begin":2276,"end":2296},"obj":"Phenotype"}],"attributes":[{"id":"A281","pred":"hp_id","subj":"T281","obj":"http://purl.obolibrary.org/obo/HP_0002098"},{"id":"A282","pred":"hp_id","subj":"T282","obj":"http://purl.obolibrary.org/obo/HP_0002098"}],"text":"Various combination of protease inhibitors, oseltamivir, favipiravir, and chloroquin for treatment of covid19: a randomized control trial Drug: oral Thailand, coronavirus infections COVID19 80, all, 16–100 Treatment Experimental: oseltamivir plus chloroquin in mild COVID19\nOseltamivir 300 mg per day plus chloroquin 1,000 mg per Day In mild COVID19\nExperimental: lopinavir and ritonavir plus favipiravir\nLopinavir 10 mg/kg and ritonavir 2.5 mg/kg plus favipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day in Mild COVID19\nExperimental: lopinavir and ritonavir plus oseltamivir in mild COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg In mild COVID19\nExperimental: lopinavir and ritonavir oseltamivir moderate to severe COVID19\nLopipinavir 10 mg/kg and ritonavir 2.5 mg/kg plus oseltamivir 4–6 mg/kg in moderate to critically ill COVID19\nExperimental: favipiravir lopinavir/ritonavir for mod. To severe\nfavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus lopipinavir 10 mg/kg and ritonavir 2.5 mg/kg in moderate to critically ill COVID19\nExperimental: darunavir/ritonavir oseltamivir chloroquine mod‐severe\nCombination of Darunavir 400 mg every 8 hr ritonavir Ritonavir 2.5 mg/kg plus Oseltamivir 4–6 mg/kg plus Chloroquine 500 mg per Day In moderate to critically ill COVID19\nExperimental: darunavir/ritonavir favipiravir chloroquine mod‐severe\nFavipiravir 2,400 mg, 2,400 mg, and 1,200 mg every 8 hr on Day 1, and a maintenance dose of 1,200 mg twice a day plus darunavir 400 mg every 8 hr ritonavir ritonavir 2.5 mg/kg plus chloroquine 500 mg per Day In moderate to critically ill COVID19\nNo intervention: conventional qurantine\nPatient who unwilling to treatment and willing to quarantine in mild COVID19 III Primary (Up to 24 weeks):\nSARS‐CoV‐2 eradication time\nSecondary (up to 24 weeks):\nNumber of patient with death, number of patient with recovery adjusted by initial severity in each arm, number of day with ventilator dependent adjusted by initial severity in each arm,number of patient developed acute respiratory distress syndrome after treatment\nOther (up to 24 weeks):\nNumber of patient with acute respiratory distress syndrome recovery NCT04303299/Not yet recruiting, Mar15‐Nov30 2020"}

LitCovid-PubTator

PMC:7283670 / 99250-101614 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7283670 / 99250-101614 JSON TXT